Nectar Lifesciences Stock Screener | Share Price & Fundamental Analysis
NECLIFE
Pharmaceuticals
Screen Nectar Lifesciences share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹20.90
▲
0.45 (2.20%)
Share Price BSE
₹19.41
▲
0.32 (1.68%)
Market Cap
₹457.04 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
0.61
EPS (TTM)
₹-5.07
Dividend Yield
-
Debt to Equity
0.60
52W High
₹20.95
52W Low
₹13.71
Operating Margin
-3534.00%
Profit Margin
-3520.00%
Revenue (TTM)
₹5.00
EBITDA
₹-177.00
Net Income
₹-176.00
Total Assets
₹2,047.00
Total Equity
₹956.00
Nectar Lifesciences Share Price History - Stock Screener Chart
Screen NECLIFE historical share price movements with interactive charts. Analyze price trends and patterns.
Nectar Lifesciences Company Profile - Fundamental Screener
Screen Nectar Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for NECLIFE shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE023H01027
Nectar Lifesciences Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen NECLIFE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 2,047 | 2,191 | 2,189 | 2,391 | 2,388 | 2,633 | 2,705 | 2,724 | 2,581 | 2,556 |
| Current Assets | 1,238 | 1,284 | 1,231 | 1,355 | 1,239 | 1,615 | 1,669 | 1,661 | 1,496 | 1,464 |
| Fixed Assets | 633 | 643 | 662 | 723 | 772 | 785 | 825 | 852 | 881 | 906 |
| Liabilities | ||||||||||
| Total Liabilities | 2,047 | 2,191 | 2,189 | 2,391 | 2,388 | 2,633 | 2,705 | 2,724 | 2,581 | 2,556 |
| Current Liabilities | 70 | 149 | 234 | 299 | 139 | 249 | 300 | 356 | 296 | 362 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 956 | 1,069 | 1,065 | 1,088 | 1,062 | 1,136 | 1,105 | 1,059 | 1,007 | 954 |
| Share Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves & Surplus | 934 | 1,047 | 1,042 | 1,066 | 1,040 | 1,114 | 1,083 | 1,036 | 984 | 932 |
Screen NECLIFE income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5 | 6 | 429 | 455 | 12 | 359 | 441 | 453 | 409 | 395 | 406 | 357 | 399 | 403 | 477 |
| Expenses | 182 | 69 | 585 | 410 | 6 | 320 | 393 | 410 | 371 | 359 | 371 | 343 | 396 | 361 | 427 |
| EBITDA | -177 | -63 | -156 | 45 | 6 | 40 | 49 | 43 | 38 | 36 | 35 | 15 | 3 | 42 | 50 |
| Operating Profit % | -3534.00% | -1212.00% | -36.00% | 10.00% | -10.00% | 11.00% | 11.00% | 9.00% | 7.00% | 9.00% | 4.00% | 0.00% | -2.00% | 10.00% | 10.00% |
| Depreciation | 0 | 1 | 16 | 16 | 0 | 16 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 14 |
| Interest | 0 | 0 | 18 | 17 | 0 | 20 | 24 | 25 | 21 | 18 | 20 | 18 | 21 | 21 | 17 |
| Profit Before Tax | -176 | -64 | -188 | 13 | 6 | 5 | 11 | 3 | 2 | 3 | 2 | -18 | -33 | 6 | 18 |
| Tax | 0 | 0 | -58 | 5 | 0 | 2 | 11 | 1 | 1 | 1 | -2 | -8 | -10 | 2 | 6 |
| Net Profit | -176 | -63 | -130 | 8 | 6 | 3 | 1 | 2 | 1 | 2 | 4 | -9 | -23 | 4 | 12 |
| EPS | -7.84 | -2.82 | -5.80 | 0.35 | 0.25 | 0.13 | 0.03 | 0.07 | 0.05 | 0.08 | 0.16 | -0.41 | -1.00 | 0.17 | 0.52 |
Nectar Lifesciences Cash Flow Screener - Liquidity Fundamentals
Screen NECLIFE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 169 | 225 | 134 | 95 | 21 | 285 | 239 | 65 | 199 | 169 |
| Investing Activities | -42 | -17 | 52 | 17 | -29 | -33 | -26 | -29 | -18 | -77 |
| Financing Activities | -128 | -205 | -186 | -119 | 12 | -252 | -201 | -40 | -204 | -89 |
| Net Cash Flow | -1 | 2 | 0 | -8 | 4 | 0 | 12 | -4 | -24 | 3 |
Screen NECLIFE shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 44.53% | 44.53% | 44.91% | 55.80% | 55.80% | 55.80% | 44.53% | 55.80% |
| FII Holding | 1.65% | 0.81% | 0.62% | 16.97% | 16.61% | 3.24% | 0.73% | 14.59% |
| DII Holding | 0.16% | 0.19% | 0.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| Public Holding | 41.60% | 44.12% | 44.70% | 23.32% | 23.69% | 30.45% | 39.36% | 24.46% |
| Other Holding | 12.04% | 10.32% | 9.67% | 3.88% | 3.87% | 10.49% | 15.35% | 5.13% |
| Shareholder Count | 69,241 | 71,977 | 76,470 | 59,946 | 58,230 | 66,741 | 69,482 | 64,422 |
Nectar Lifesciences Dividend Screener - Share Yield Analysis
Screen NECLIFE dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.05 | 0.27% |
| 2019-March | ₹0.05 | 0.51% |
| 2018-March | ₹0.05 | 0.29% |
| 2017-March | ₹0.05 | 0.19% |
| 2016-March | ₹0.00 | 0.00% |
Nectar Lifesciences Index Membership - Market Screener Classification
Screen NECLIFE by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Nectar Lifesciences Market Events Screener - Corporate Actions
Screen NECLIFE market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -5.38% | ||
| Annual General Meeting | NA | 41.10% | ||
| 2025-12-24 | 2026-12-31 | Buyback | 27 | -4.28% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 8.67% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | 8.63% |
| 2025-08-04 | 2025-08-04 | Extraordinary General Meeting | NA | -28.60% |
| 2025-07-07 | 2025-07-07 | Quarterly Result Announcement | NA | -9.14% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | -18.01% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -11.31% |
Nectar Lifesciences Competitors Screener - Peer Comparison
Screen NECLIFE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.35 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,413 | 68.31 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,247 | 60.76 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.46 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,613 | 18.49 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,056 | 22.19 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,075 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,356 | 51.11 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,290 | 20.05 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,324 | 27.31 | 13,458 | 3.70% | 2,216 | 38.49 |
Nectar Lifesciences Company Announcements - News Screener
Screen NECLIFE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2026-01-04 | Letter Of Offer For Buyback | View |
| 2026-01-02 | Closure of Trading Window | View |
| 2025-12-20 | Transfer Of The Business On A Slump Sale Basis | View |
| 2025-12-15 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | View |
| 2025-12-10 | Announcement under Regulation 30 (LODR)-Public Announcement-Buyback of Shares | View |
| 2025-12-05 | Announcement under Regulation 30 (LODR)-Public Announcement-Buyback of Shares | View |
| 2025-12-03 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-12-03 | Fixed Record Date For Buyback | View |
| 2025-12-03 | Board Meeting Outcome for Meeting Held On December 03 2025 | View |
| 2025-11-28 | Disclosure Under Regulation 7(2) Of Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations 2015 | View |
| 2025-11-27 | Closure of Trading Window | View |
| 2025-11-27 | Board Meeting Intimation for Proposal For Buyback Of Equity Shares Of The Company | View |
| 2025-11-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-14 | Board Meeting Outcome for Outcome Of Board Meeting | View |
| 2025-11-14 | Results For Quarter And Half Year Ended September 30 2025. | View |
| 2025-11-13 | Update On Slump Sale | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-11-11 | Update On Slump Sale | View |
| 2025-11-09 | Announcement under Regulation 30 (LODR)-Change in Management | View |